Oxford Biomedica PLC ORD 50P
Oxford Biomedica PLC ORD 50P/ GB00BDFBVT43 /
OXB
2024-10-10 9:00:00 PM
|
Chg.
+0.5000
|
Volume |
Bid2024-10-10 |
Ask2024-10-10 |
Market Capitalization |
Dividend Y. |
P/E Ratio |
385.5000GBX
|
+0.13%
|
28,799 Turnover(GBP): 111,019.7700 |
292.0000Bid Size: 1,697 |
390.0000Ask Size: 1,228 |
308.1 mill.GBP |
- |
- |
Business description
Oxford BioMedica is a pioneer of gene and cell therapy, with a leading industry position in lentiviral vector and cell therapy research, development and manufacture.
Management board & Supervisory board
CEO |
John Dawson |
Management board |
Stuart Paynter, Helen Stephenson-Ellis, James Miskin, Jason Slingsby, Kyriacos Mitrophanous, Matthew Treagus, Natalie Walter, Nick Page |
Supervisory board |
Dr. Roch Doliveux, Dr. Michael Hayden, Dr. Sam Rasty, Heather Preston, John Dawson, Prof. Dame Kay Davies, Robert Ghenchev, Stuart Henderson, Stuart Paynter |
Main Shareholders
Freefloat |
|
50.20% |
Vulpes Investment Management |
|
11.90% |
Novo Holdings |
|
10.00% |
M&G Investments |
|
8.70% |
Liontrust Asset Management |
|
5.00% |
Nine Ten Capital |
|
3.80% |
Hargreaves Lansdown Asset Management |
|
3.70% |
Mr. S M H Shah |
|
3.50% |
Artisan Partners |
|
3.20% |